NCT04257149

Brief Summary

This is a prospective, open, multicentre trial that will enrol patients with clinical signs of stroke in the acute phase admitted for CT scan. The study assesses the diagnostic capability and safety of Strokefinder MD100.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
500

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Feb 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

4 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 1, 2018

Completed
Same day until next milestone

Study Start

First participant enrolled

February 1, 2018

Completed
2 years until next milestone

First Posted

Study publicly available on registry

February 5, 2020

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2022

Completed
3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2025

Completed
Last Updated

February 5, 2020

Status Verified

February 1, 2020

Enrollment Period

4 years

First QC Date

February 1, 2018

Last Update Submit

February 4, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • To evaluate the diagnostic ability of the device to diagnose hemorrhagic stroke and ischemic stroke in the prehospital and hospital setting

    The diagnostic ability as measured by the area under the curve of the device for patient groups (group C vs. groups A + B) using the LOOCV method

    Baseline

Secondary Outcomes (4)

  • Adverse events within 24 hours

    Baseline to 24 hours

  • To evaluate the diagnostic ability of the device to differentiate patients with stroke mimics

    Baseline

  • To evaluate the delivery of adequate measurement data from the device

    Baseline

  • To evaluate the amount of time needed to perform the measurement procedures

    Basline

Study Arms (3)

Hemorrhagic stroke group (group A)

EXPERIMENTAL

Patient group A is defined as patients that are diagnosed with hemorrhagic stroke.

Diagnostic Test: Hemorrhagic stroke group (group A)

Ischemic stroke group (group B)

EXPERIMENTAL

Patient group B is defined as patients that are diagnosed with ischemic stroke.

Diagnostic Test: Ischemic stroke group (group B)

Stroke mimic group (group C)

EXPERIMENTAL

Patient group C is defined as patients with stroke mimics, i.e. with initially suspected stroke but not diagnosed with stroke.

Diagnostic Test: Stroke mimic group (group C)

Interventions

Group A: A microwave measurement (Stroke finder MD100) will be performed with the patient lying on the ambulance stretcher, in the hospital bed or another suitable surface.

Hemorrhagic stroke group (group A)

Group B: A microwave measurement (Stroke finder MD100) will be performed with the patient lying on the ambulance stretcher, in the hospital bed or another suitable surface.

Ischemic stroke group (group B)

Group C: A microwave measurement (Stroke finder MD100) will be performed with the patient lying on the ambulance stretcher, in the hospital bed or another suitable surface.

Stroke mimic group (group C)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient with clinical signs of stroke
  • Patient should be ≥ 18 years of age
  • Patient/next of kin confirms orally that the patient wants to participate in the trial (during acute phase)
  • Signed Informed Consent Form (after acute phase)

You may not qualify if:

  • Pregnant or nursing woman
  • Fertile woman where pregnancy cannot be excluded
  • Patient diagnosed with a condition associated with risk of poor protocol compliance
  • The diagnostic procedure is deemed to interfere with the standard of care
  • Any other condition or symptoms preventing the patient from entering the study, according to the investigator´s judgment
  • Any patient that according to the Declaration of Helsinki is deemed unsuitable for study enrolment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Haukeland University Hospital

Bergen, Norway

RECRUITING

Norlandsykehuset HF

Bodø, Norway

NOT YET RECRUITING

Statoil As

Stavanger, 4017, Norway

RECRUITING

Stavanger University Hospital

Stavanger, 4017, Norway

RECRUITING

MeSH Terms

Conditions

StrokeCerebral Hemorrhage

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesIntracranial HemorrhagesHemorrhagePathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Martin Kurz, PhD

    Helse Stavanger HF

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Martin Kurz, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 1, 2018

First Posted

February 5, 2020

Study Start

February 1, 2018

Primary Completion

February 1, 2022

Study Completion

February 1, 2025

Last Updated

February 5, 2020

Record last verified: 2020-02

Data Sharing

IPD Sharing
Will not share

Locations